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Abstract: This mini review is to introduce the readers of Plasma to the field of plasma medicine.
This is a multidisciplinary field of research at the intersection of physics, engineering, biology and
medicine. Plasma medicine is only about two decades old, but the research community active in this
emerging field has grown tremendously in the last few years. Today, research is being conducted on a
number of applications including wound healing and cancer treatment. Although a lot of knowledge
has been created and our understanding of the fundamental mechanisms that play important roles in
the interaction between low temperature plasma and biological cells and tissues has greatly expanded,
much remains to be done to get a thorough and detailed picture of all the physical and biochemical
processes that enter into play.
Keywords: low temperature plasma; plasma jet; cells; tissue; apoptosis; cancer; wound healing;
reactive species
1. Introduction
In the mid-1990s, experiments were conducted that showed that low temperature atmospheric
pressure plasmas (LTP) can be used to inactivate bacteria [1]. Based on these results, the Physics and
Electronics Directorate of the US Air Force Office of Scientific Research (AFOSR) funded a proof of
principle research program in 1997 and supported such research for a number of years. The results from
this research program were widely disseminated in the literature, including in peer-reviewed journals
and conference proceedings, therefore attracting the attention of the plasma physics community to new
and emerging applications of low temperature plasma in biology and medicine [2–8]. The goals of the
AFOSR program were to apply low temperature plasmas (LTP) to treat the wounds of injured soldiers
and to sterilize/disinfect both biotic and abiotic surfaces. By the early 2000s, research expanded to
include eukaryotic cells when small doses of LTP were found to enhance phagocytosis, accelerate
the proliferation of fibroblasts, detach mammalian cells without causing necrosis, and under some
conditions, lead to apoptosis [9,10].
The above-described groundbreaking research efforts showed that nonthermal plasma can gently
interact with biological cells (prokaryotes and eukaryotes) to induce certain desired outcomes. These
early achievements raised great interest and paved the way for many laboratories from around the
world to investigate the biomedical applications of LTP and by the end of the first decade of the 2000s,
a global scientific community was established around such research activities. The field is today known
by the term plasma medicine, and in the last few years a number of extensive reviews and tutorials
were published (see Refs [11–18] and references therein) as well as a few books [19–21].
Today, the field of plasma medicine encompasses several applications of low temperature plasmas
in biology and medicine [22–53]. These include:
- Sterilization, disinfection, and decontamination,
- plasma-aided wound healing
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- plasma dentistry
- cancer applications or “plasma oncology,”
- plasma pharmacology,
- plasma treatment of implants for biocompatibility.
In the late 2000s, several LTP sources were approved for cosmetic and medical use. Examples are:
in 2008 the US FDA approved the Rhytec Portrait® (plasma jet) for use in dermatology. Also in the US
other plasma devices are in use today for various medical applications, such as the Bovie J-Plasma®
and the Canady Helios Cold Plasma and Hybrid PlasmaTM Scalpel. In Germany, the medical device
certification class IIa was given to the kINPen® (plasma jet) in 2013, and the PlasmaDerm® device
(CINOGY GmbH) was also approved. Figure 1 is a timeline graph showing the major milestones in
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healthcare  challenges are  linked  to nosocomial  infections  caused by antibiotic  resistant  strains of 
bacteria, such as Methicillin‐resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C‐diff). 
Every  year  in  the  US,  hospital  acquired  infections  (HAI)  kill  thousands  of  patients  with 
compromised  immune  systems. HAI  are  caused  by  inadequate  sterilization/decontamination  of 
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investigators  reported  experiments  showing  that  low  temperature  plasmas  (LTP)  can  destroy 
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Figure 1. i eli e s i s e ajor ilestones of the new field of the biomedical applications
of low temperature atmospheric pressure plasma. This timeline does not show the case of thermal
(hot) plasmas, which were used for many decades in medical applications requiring heat, such as
cauterization and blood coagulation.
2. TP Takes on Hygiene and Medical Chal enges
s can be seen fro Figure 1 the bio edical applicatio s of LTP started ith experi ents on
the inactivation of bacteria on biotic and abiotic surfaces and edia. acterial c ta i ati rove
to pose severe chal enges for so e industries and in the healthcare arena. The industrial chal enges
are ainly around the proble of food contamination and sterilization of food packaging. Several
el -publicize foo poisoni inci e ts ( , Listeria, Sal o ella) oi te o t to consu ers that
t e e ployed by the f od industry may not be adequate to insure food safety.
The healthcare chall nges are linked to n s comial infections caused by antibiotic of
bacteri , s c as ethicil i -resist t ta l l fi -
Every year in the US, hospital acquired infections (HAI) kill thousands of patie ts with compromised
im une systems. HAI are caused by inadequate sterilization/decontam nation of instruments,
surfaces, clothing, bedsheets, and personnel ( urs s a d docto ). In most cases, contamination
by s rains of bacteria resistant to the best a tibiotic medica ons available t day is the cause of HAI.
LTP is therefore considered as a novel technology that can be successfully applied to help solve some
of the challenges described above.
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The most recent application presently receiving much attention is the use of LTP to destroy cancer
cells and tumors in a selective manner [38–58]. Starting around the mid-2000s several investigators
reported experiments showing that low temperature plasmas (LTP) can destroy cancerous cells in vitro.
This was followed by some in vivo work showing that LTP can reduce the size of cancer tumors in
animal models. The in vitro work covered a host of cancerous cell lines, which included glioblastoma,
melanoma, papilloma, carcinoma, colorectal cancer, ovarian cancer, prostate cancer cells, squamous cell
carcinoma, leukemia, and lung cancer. The in vivo (animal model) work can be found in [38,44,45,53].
In addition to direct plasma applications to cancer cells and tissues, investigators reported that
plasma-activated media (PAM) can also be used to destroy cancer cells [38,50,54–58]. Plasma-activated
medium is produced by exposing a biological liquid medium to LTP for a length of time (minutes). In
this case, the plasma-generated reactive species interact with the contents of the medium and generate
solvated long-lived reactive species in the liquid, such as hydrogen peroxide, H2O2, nitrite, NO2−,
nitrate, NO3−, peroxynitrite. ONOO−, and organic radicals. These molecules subsequently react with
the cells and tissues causing various biological outcomes.
3. Mechanisms of Biological Action of LTP: Brief Summary
Investigators reported that the effects of LTP on biological cells (prokaryotes and eukaryotes)
are mediated by reactive oxygen and nitrogen species (RONS) [11,12,59–66]. These species include
hydroxyl, OH, atomic oxygen, O, singlet delta oxygen, O2(1∆), superoxide, O2−, hydrogen peroxide,
H2O2, and nitric oxide, NO. For example, the hydroxyl radical is known to cause the peroxidation of
unsaturated fatty acids, which make up the lipids constituting the cell membrane. The biological effects
of hydrogen peroxide are mediated by its strong oxidative properties affecting lipids, proteins, and
DNA (single and possibly double-strand breaks). Nitric oxide, which acts as an intracellular messenger
and regulator in biological functions, is known to affect the regulation of immune deficiencies, cell
proliferation, induction of phagocytosis, regulation of collagen synthesis, and angiogenesis.
In cancer cells, the mechanisms of action of LTP are suspected to be related to an increase of
intracellular reactive oxygen species (ROS), which can lead to cell cycle arrest at the S-phase, DNA
double-strand breaks, and induction of apoptosis. Research by various groups showed that RONS
generated by LTP react with cell membranes and can even penetrate the cells and induce subsequent
reactions within the cells that can trigger cell-signaling cascades, which can ultimately lead to apoptosis
in cancer cells [56–66]. In addition, investigators have shown that plasma-generated RONS can indeed
penetrate biological tissues up to depths of more than 1 mm and therefore interact not only with the
cells on the surface but with those underneath [67–72].
LTP delivers not only reactive species but it also can exhibit large enough electric fields [73–77].
The magnitudes of these electric fields are several kV/cm and they are suspected to play a role, such
as in cellular electroporation, which may allow large molecules to enter the cells.
4. Two LTP Sources for Biomedical Applications: Brief Description
The main LTP devices used in plasma medicine research are the dielectric barrier discharge
(DBD) and nonequilibrium atmospheric pressure plasma jets (N-APPJ). In fact, the DBD was the
device used in the first experiments on the inactivation of bacteria [1]. The DBD uses plate electrodes
covered by a dielectric (such as glass). The plasma is generated in the gap separating the electrodes
by the application of high sinusoidal voltages in the kHz frequency range. Gases such helium with
admixtures of oxygen or air are usually used. For more information on the working of the DBD see
references [61,78,79]. Figure 2 shows a schematic of the DBD and a photograph of a diffuse plasma at
atmospheric pressure generated by a DBD.














configurations  ranging  from single electrode,  to  two‐ring electrodes wrapped around  the outside 
wall of a cylindrical dielectric body, to two‐ring electrodes attached to centrally perforated dielectric 











modeling, by various  investigators  [85–91]. Today  there  is agreement  that  the plasma bullets are 
guided ionization waves. To learn about these guided ionization waves in greater detail, the reader 
is referred to [92]. 
Figure 2. Schematic (a) and a photograph (b) of an atmospheric pressure diffuse plasma generated by a
dielectric barrier discharge (DBD). The discharge in the photo on the right is driven by kHz sinusoidal
high voltage and the gas is helium with a small admixture of air. Photo taken at the author’s laboratory.
Nonequilibrium atmosp eric pressure plasma jets (N-APPJs) produce plasma plumes that
propagat away from the confinement of electrodes and into the ambient air. The reactive species
generated by the plasma can therefore sa ely and convenie ly b transported to a target at a remote
location and away from the main plasma generation area. This characteristic made N-APPJs very
attractive tools for applications i biology and medicine [60,80–82]. V rious power driving methods
that include pulsed DC, RF, and micr wave power have been used. In addition, various electr e
configurations ranging from si gle electrode, to t o-ring lectrodes wrappe ar und the outside wall
of a cylindrical dielectric body, to two-ring el ctrodes attach d to centrally erfor ted dielectric disks
h ve been used. Figure 3 shows ph tographs of two N-APPJs, the plasm pencil and the kINPen,
which have extensively in plasma medicine research.
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Figure 2. Sche atic  (left) and a photograph of an at ospheric pressure diffuse plas a 
generated by a dielectric barrier discharge ( B ). The discharge in the photo on the right 
is driven by k z sinusoidal high voltage and the gas is heliu   ith a s all ad ixture of 
air. Photo taken at the author’s laboratory. 
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traveling at very high velocities (tens of k /s). These plas a packets ca e to be kno n as “plas a 
bullets” and they  ere independently first reported in the  id‐2000s by Teschke et al and by Lu and 
Laroussi [83,84]. Lu and Laroussi used nanosecond‐pulsed  C po er  hile Teschke et al used RF 
po er. The plas a bullets  ere subsequently researched extensively, both experi entally and by 
odeling, by various  investigators  [85–91]. Today  there  is agree ent  that  the plas a bullets are 
guided ionization  aves. To learn about these guided ionization  aves in greater detail, the reader 
is referred to [92]. 
Figure 3. Photographs of two plasma jets that have been used in various biomedical applications. (a) is
the plasma pencil (ODU, Norfolk, VA, USA), and (b) is the kINPen (INP, Greifswald, Germany).
The plasma plumes emitted by N-APPJs turned out to be made of small plasma packets traveling
at very high velocities (t ns of km/s). These pla ma packets came to be known as “p asma bullets” and
they were ind pendently firs reported in the mid-2000s by Teschke et al and by Lu and Laroussi [83,84].
Lu and Laroussi us d nanosecond-pulsed DC power w ile Teschke et al used RF power. The plasma
bullet were subsequently researched exte sively, both experimentally and by modeling, by various
investigators [85–91]. Today there is agreement that the plasma bullets are guided ioniz tion waves.
To lear about these guided ionization waves in greater detail, the reader is referred to [92].
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5. Two Biomedical Applications of LTP
To illustrate the effects of LTP on biological targets, two applications are shown here. The first
concerns the bactericidal property of LTP and the second shows the effects of direct plasma exposure as
well as plasma activated media on cancerous and healthy epithelial cells. The results presented below
are based on the use of the plasma pencil described earlier. The results shown were obtained by the
application of the LTP plume generated by the plasma pencil on a bacterial lawn seeded on the surface
of a Petri dish (see Figure 4). The bacterium used was Acinetobacter calcoaceticus, a gram-negative soil
bacterium also found in the tiger mosquito, which is known to be a transmission vector of yellow and
dengue fevers. Figure 5 shows zones of inactivation (dark circular areas) around the center of the dish
where the plasma plume was applied. The photo to the left is for an initial bacteria concentration of
109/mL, while that on the right is for an initial concentration of 107/mL. It is clear that the killing
effects are more extended and pronounced for the lower initial concentration. For more information
on the dependence of inactivation on the plasma exposure time and on the type of bacteria, the reader
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Figure 4. Experi ental setup for the bacterial inactivation experi ents.
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Figure 5. Killing property of LTP: Dependence of the killing efficacy on the initial bacteria concentration.
Left picture is for 109/mL and right picture is for 107/mL. Bacterium is A. calcoaceticus. LTP source is
the plasma pencil operated with helium as a carrier gas [93].
Figure 6 shows the effects of direct application of LTP on suspensions of cancerous cells. The cancer
cell line used was a squamous cell carcinoma of the bladder (SCaBER, ATCC HTB-3TM) originally
obtained from a human bladder. After LTP exposure and proper incubation process (37 °C under
5% CO2 atmosphere), Trypan-blue exclusion assay was used to count the number of live and dead
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cells. For details of the experimental protocol please refer to [40]. The counts immediately after LTP
treatment (at 0 h) revealed no dead cells, which suggested there were no immediate physical effects.
However, the viability of cells reduced to around 50% at 24 h after a 2-min LTP treatment. As seen
in Figure 6, higher plasma exposure times result in more cells killed (5-min plasma treatment results
in 75% of loss of viability at 24 h post-treatment) [40]. These results indicate that LTP does not apply
immediate brute physical force on the cells, but its effects require longer biological times to show. This
is an indication that plasma agents, such as reactive species and electric fields, interact with the cells
and induce reactions and/or trigger biochemical pathways that ultimately result in the death of the
cancer cells hours later.
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Figure  7. Viability  in percent of  SCaBER  (cancerous)  and MDCK  cells  (noncancerous)  treated by 
PAM for various lengths of time. Viability was assessed after 12 hours incubation with PAM using 
MTS assay and Trypan‐blue exclusion assay [57]. 
Figure 6. Viability of SCaBER cells in media treated directly by the LTP plume of the plasma pencil
reveal dead (black bars on top) and live (green bars) cells. The viability was monitored at 0, 12, 24 and
48h post-LTP tre tment [40].
Figure 7 shows the selective effect of LTP when it comes to destroying cancer cells versu healthy
cells in vitro. The viability results shown in the figure below were obtained using lasma act vated
media (PAM), which was created by exposing biological liquid media to the plasma pencil for certain
lengths of time. The cancerous cell line used was SCaBER and the healthy/normal cells were MDCK
(Madin-Darby canine kidney) cells from normal epithelial tissue of a dog kidney. The media used to
make PAM were MEM (minimum essential media) for SCaBER and Eagle Minimum Essential Media
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Figure 7 shows that PAM created using longer exposures to LTP has increasing killing effects on
SCaBER cancer cells, reducing their viability to below 10% for irradiation times longer than 2 min.
However, normal MDCK cells were able to withstand exposure to PAM for 3 min. This illustrates the
selectivity of PAM in killing cancer cells while sparing healthy cells. But for PAM created with longer
exposures to LTP (6 minutes and more) extensive killing of MDCK cells was obtained. This illustrates
that the plasma dose is an important factor to take into consideration for optimal outcomes.
6. Penetration of RONS in Tissues
One of the key questions in plasma medicine is the following: Do the RONS generated by LTP only
interact and affect cells on the surface of a tissue (or tumor) or do they penetrate the tissue and affect
cells in deeper layers? Experimental evidence has shown that LTP does indeed affect cells underneath
the tissue surface but what remains unclear is how. One possible explanation is what is referred to as
the “bystander effect,” which implies that there are chemical signals sent by the cells on the surface
(in contact with plasma) to cells in the layer below [41]. These signals would trigger reactions similar
to those occurring at the cells on the surface, including the onset of apoptosis. However, and to the
best of this author’s knowledge, there has been no experimental proof this occurs when LTP interacts
with tissues. So, the possibility is there, but reliable data that can be replicated needs to emerge first.
Therefore, in this section, only experiments that reported qualitatively and/or quantitatively on the
penetration of RONS are presented.
In order to qualitatively and quantitatively elucidate RONS penetration into tissues, investigators
used various in vitro models. Oh et al. investigated the penetration of RONS using a model made of
an agarose film covering a volume of deionized water contained in a quartz cuvette [67]. They found
that RONS kept being delivered from the agarose film to deionized water underneath it for up to
25 min after the plasma was removed. To study the delivery of reactive oxygen species (ROS) into cells,
Hong et al. used a model comprising phospholipids vesicles encapsulated within a gelatin matrix and
equipped with reactive oxygen species (ROS) reporter [68]. They found that ROS were delivered to
the cells without rupturing the membranes of the vesicles. To simulate biological tissue, Szili et al.
used gelatin gel, a derivative of collagen, and reported on the penetration behavior of H2O2 through a
1.5 mm thickness gelatin film [69]. The same authors also investigated the effects on DNA in synthetic
tissue fluids, tissue, and cells [94].
Tissue models are useful and provide preliminary data regarding the penetration of RONS
through biological targets. However, to simulate more realistic conditions, Duan et al. used slices of
pig muscle tissue of different thicknesses placed on top of a PBS solution [72]. Figure 8 shows the
experimental setup. A plasma jet operated with a helium/oxygen mixture was used. To ignite the
plasma sinusoidal high voltages at a frequency of 1 kHz were employed. The plasma treatment times
were 0, 5, 10, and 15 min.














Figure 8. Experimental setup using pig muscle tissue [72]. Reproduced from Duan, J.; Lu, X.; and He,
G. Phys. Plasmas 2017, 24, 073506, with the permission of AIP Publishing.
The concentrations of H2O2, OH, and that of the total of (NO2− + NO3−) were measured for
different thicknesses of the tissue slice. A comparison of these concentrations when no tissue was
used and when a tissue was placed on top of the solution showed that the concentrations of O3, OH,
and H2O2 were mostly consumed by the tissue and could not pass through 500-µm or greater tissue
thickness. However, more than 80% of the (NO2− + NO3−) penetrated a 500-µm-thick tissue slice.
Figure 9 shows the measured concentrations of (NO2− + NO3−) as a function of tissue thickness and
for three plasma treatment times (5, 10, and 15 min).
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Figure 9. Total nitrite and nitrate concentration versus  tissue  thickness  for  three plasma exposure 
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biomedical  applications  of  low  temperature  plasma  have  opened  up  an  entirely  new 
multidisciplinary  field  of  research  requiring  close  collaboration  between  physicists,  engineers, 
biologists, biochemists, and medical experts. This multidisciplinary field started in mid‐1990s with 
seminal  experiments  on  the  inactivation  of  bacteria  by  low  temperature  atmospheric  pressure 
plasma generated by a dielectric barrier discharge and slowly expanded to include investigations on 
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innovative  medical  therapies  can  be  developed  to  overcome  present  healthcare  challenges. 






Figure 9. Total nitrite and nitrate concentration versus tissue thickness for three plasma exposure
times [72]. Reproduced from Duan, J.; Lu, X.; and He, G. Phys. Plasmas 2017, 24, 073506, with the
permission of AIP Publishing.
Figure 9 shows that the concentrations of the nitrogen reactive species, RNS, decrease with the
tissue thickness, but increase with the plasma treatment time. The concentration of (NO2− + NO3−)
for the 500-µm tissue thickness was comparable to the concentration when no tissue was placed on top
of the PBS solution. This means that (RNS) were able to penetrate the tissue slice. This was not the
case for ROS, which were absorbed by the tissue, unlike the case when a gelatin model (not real tissue)
was used. For that odel, ROS were able to penetrate the gelatin film.
The above examples illustrate that RONS do not simply react with the surface of tissues but can
indeed penetrate relatively deeply. However, in more realistic conditions using actual tissue, it was
shown that not all RONS can cross the same thickness. Some can be absorbed within a few tens of
micrometers by the tissue, while others can penetrate up to 1.5 mm below the surface. Of course,
the above results may not completely reflect what would happen under in vivo conditions. Such
experiments need to be conducted and compared to results obtained for in vitro models and to those
obtained under ex vivo conditions [95].
7. Conclusions
To conclude this brief introduction of the field of plasma medicine, it is safe to say that the
biomedical applications of low temperature plasma have opened up an entirely new multidisciplinary
field of research requiring close collaboration between physicists, engineers, biologists, biochemists,
and medical experts. This multidisciplinary field started in mid-1990s with seminal experiments on
the inactivation of bacteria by low temperature atmospheric pressure plasma generated by a dielectric
barrier discharge and slowly expanded to include investigations on eukaryotic cells. Applications
in dermatology, wound healing, dentistry, and cancer have led to various scientific advances and
to the idea that LTP can be a technology upon which various innovative medical therapies can be
developed to overcome present healthcare challenges. However, a lot remains to be done in order to
fully understand the mechanisms of action of LTP against biological cells and tissues, both in vitro
and in vivo. There is strong indication that LTP acts selectively on cancer cells and tumors and can
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before LTP can be considered a safe technology ready for use in hospitals to treat chronic wounds,
cancer lesions and tumors, and other ailments.
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